Vaccine-induced and naturally-acquired protection against Omicron and Delta symptomatic infection and severe COVID-19 outcomes, France, December 2021 to January 2022-Reference-Cited by-同舟云学术

Vaccine-induced and naturally-acquired protection against Omicron and Delta symptomatic infection and severe COVID-19 outcomes, France, December 2021 to January 2022

Published:2022-04-21 Issue:16 Volume:27 Page:
ISSN:1560-7917
Container-title:Eurosurveillance
language:en
Short-container-title:

Author:

Suarez Castillo Milena¹²^ORCID,Khaoua Hamid¹,Courtejoie Noémie¹^ORCID

Affiliation:

1. The Health and Solidarity Ministerial Statistical Department (DREES), Paris, France

2. French national institute for statistical and economic studies (INSEE), Montrouge, France

Abstract

We assessed the protection conferred by naturally-acquired, vaccine-induced and hybrid immunity during the concomitant Omicron and Delta epidemic waves in France on symptomatic infection and severe COVID-19. The greatest levels of protection against both variants were provided by hybrid immunity. Protection against Omicron symptomatic infections was systematically lower and waned at higher speed than against Delta in those vaccinated. In contrast, there were little differences in variant-specific protection against severe inpatient outcomes in symptomatic individuals.

Publisher

European Centre for Disease Control and Prevention (ECDC)

Subject

Virology,Public Health, Environmental and Occupational Health,Epidemiology

Reference14 articles.

1. Santé publique France (SPF). COVID-19 - Point épidémiologique hebdomadaire du 23 décembre 2021. [COVID-19 weekly epidemiological report of 23 December 2021]. Saint-Maurice: SPF. 23 Dec 2021. French. Available from: https://www.santepubliquefrance.fr/content/download/400096/3305200

2. European Centre for Disease Prevention and Control (ECDC). Reinfection with SARS-CoV-2: implementation of a surveillance case definition within the EU/EEA. 8 April 2021. ECDC: Stockholm, 2021. Available from: https://www.ecdc.europa.eu/en/publications-data/reinfection-sars-cov-2-implementation-surveillance-case-definition-within-eueea

3. Vaccine effectiveness and duration of protection against symptomatic and severe Covid-19 during the first year of vaccination in France;Suarez Castillo;MedRxiv,2022

4. SARS-CoV-2 reinfections: Overview of efficacy and duration of natural and hybrid immunity.;Pilz;Environ Res,2022

5. Covid-19 vaccine effectiveness against the omicron (B. 1.1. 529) variant.;Andrews;N Engl J Med,2022

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of Omicron and Delta Variants of SARS-CoV-2: A Systematic Review of Current Evidence;Infectious Disorders - Drug Targets;2024-11

2. Planning and adjusting the COVID-19 booster vaccination campaign to reduce disease burden;Infectious Disease Modelling;2024-09

3. Pediatric antibody responses to SARS-CoV-2 after infection and vaccination in Calgary, Canada;BMC Infectious Diseases;2024-07-18

4. Declining Levels of Neutralizing Antibodies to SARS-CoV-2 Omicron Variants Are Enhanced by Hybrid Immunity and Original/Omicron Bivalent Vaccination;Vaccines;2024-05-22

5. COVID‐19 vaccination: are more jabs needed or are we now immune?;Internal Medicine Journal;2024-02-27